Until well-designed, adequately powered human trials clarify whether it offers real, reproducible benefits and an acceptable safety profile, it will remain outside the boundary of approved medicine
BPC-157 at 0.00068 mg/lb or 0.0000068 mg/lb given before or after each MPTP dose improved somatosensory orientation, reduced hyperactivity and motor abnormalities, and achieved almost complete abolition of MPTP-induced mortality in rats
it's just what happens when you don't make Google work hard
The Clinical Data: CagriSema Crushes Either Peptide Alone Let me give you the numbers that matter, straight from the Phase 3 REDEFINE trials published in the New England Journal of Medicine
Doses from 0.00001 mg/kg to 0.01 mg/kg showed comparable efficacy, suggesting the peptide has a broad therapeutic window
Even a favorable discussion would still require FDA follow-up